Posted in | News | Nanomedicine | Nanobusiness

Complete Genomics Announces Partnership to Conduct First Human Genome Population Study

Complete Genomics, Inc., a newly-launched, third-generation human genome sequencing company, and the Institute for Systems Biology (ISB) today announced their partnership to conduct population-wide human genome studies.

In phase one of the project, Complete Genomics will use its proprietary DNA sequencing technology to sequence five genomes from samples provided by ISB. Then, once proof-of-concept has been demonstrated, ISB and Complete Genomics plan to expand this collaboration to sequence the genomes of 100 individuals in 2009 and 2,000 individuals in 2010.

“Using Complete Genomics human genome sequencing services to gather population-wide human genetic data will allow us to gain a more complete understanding of the genetic components and molecular processes of diseases in order to better manage, treat and prevent human disease and better understand human health,” said Dr. Leroy Hood, president of ISB and member of Complete Genomics’ Scientific Advisory Board.

“This collaboration demonstrates the value of our sequencing service business model and underscores our vision of using our large-scale, low-cost DNA sequencing technology to elucidate disease pathways,” said Dr. Clifford Reid, chairman, president and CEO of Complete Genomics. “We are pleased to be partnering with such a renowned organization as the Institute for Systems Biology on a project that will provide the data that researchers need to develop better drugs, therapeutics and diagnostics.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.